CD19 and neoplasm: CD19 antigen appears to be a highly attractive target for CAR-T therapy due to several main reasons: (1) it is ubiquitously expressed on tumor cells; and (2) apparent damage to patient’s adaptive immunity upon loss of B-cells could be successfully overcome with immunoglobulin replacement therapy.